

RESTRICTED SECURITIES

Creso Pharma Limited confirms the following securities will be subject to ASX escrow for the periods outlined below.

Securities restricted for 24 months from date of quotation

Securities	Restriction Period
8,000,001 Ordinary Fully Paid Shares	24 months from date of quotation
2,500,000 Broker Options ¹	24 months from date of quotation
250,000 SB Options ²	24 months from date of quotation
20,400,000 Performance Rights ⁴	24 months from date of quotation

Securities restricted for 12 months from date of issue

Securities	Restriction Period
6,412,500 Ordinary Fully Paid Shares	12 months from 19 January 2016
5,700,000 Ordinary Fully Paid Shares	12 months from 22 February 2016
4,342,500 Ordinary Fully Paid Shares	12 months from 13 April 2016
1,395,000 Ordinary Fully Paid Shares	12 months from 21 June 2016
712,500 Ordinary Fully Paid Shares	12 months from 14 July 2016
135,000 Ordinary Fully Paid Shares	12 months from 18 July 2016
1,000,000 Ordinary Fully Paid Shares	12 months from 13 October 2016 *These securities will be subject to an additional 12 months of voluntary escrow. Accordingly, will be restricted for a total of 24 months from the date of issue.
400,000 Scientific Committee Options ³	12 months from 27 June 2016
2,886,250 BioLingus Options ⁵	12 months from 13 October 2016
1,000,000 Performance Shares ⁶	12 months from 13 October 2016 *These securities will be subject to an additional 12 months of voluntary escrow. Accordingly, will be restricted for a total of 24 months from the date of issue.



ABN: 89 609 406 911

Notes:

1. Broker Options are exercisable at \$0.20 on or before 3 years from 13 October 2019. The full terms of the Options are set out in Section 12.3 of the replacement prospectus dated 8 August 2016 and an announcement made on or about the date of this announcement.
2. SB Options are exercisable at \$0.40 on or before 2 years from the date the Company is admitted to Official Quotation of the ASX. The full terms of the Options are set out in Section 12.3 of the replacement prospectus dated 8 August 2016 and an announcement made on or about the date of this announcement.
3. The full terms of the Performance Rights are set out in Section 12.5 of the replacement prospectus dated 8 August 2016 and an announcement made on or about the date of this announcement.
4. Scientific Committee Options are exercisable at \$0.40 on or before 27 June 2020. The full terms of the Options are set out in Section 12.4 of the replacement prospectus dated 8 August 2016 and an announcement made on or about the date of this announcement.
5. BioLingus Options exercisable at \$0.20 on or before 4 years from the date the Company is admitted to Official Quotation of the ASX. The full terms of the Options are set out in Section 12.3 of the replacement prospectus dated 8 August 2016 and an announcement made on or about the date of this announcement.
6. The full terms of the Performance Shares are set out in Section 12.6 of the replacement prospectus dated 8 August 2016 and an announcement made on or about the date of this announcement.